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are starting to bear fruit. Patients with high sun sensitivity
manage to better protect themselves from sun exposure but,
despite this, there is a strong need to reinforce sun exposure risk
awareness in the general population.
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OBJECTIVES: To examine the literature on impacted cerumen
with speciﬁc reference to pharmacological ceruminolytic agents,
its epidemiology and current management in primary care.
METHODS: A systematic literature review was undertaken by
an electronic search of the Medline, Embase, Health Star,
Current Contents, NHSEED and Cochrane databases. The
search terms for the database included “cerumen”, “ear wax”
and “hearing loss” and included papers published between
January 1, 1990 and July 31, 2002. RESULTS: Impacted
cerumen is commonly seen in primary care settings. Between 1.2
million and 3.5 million people in the UK suffer from impacted
cerumen. Moreover, 2.3 million people in the UK suffer cerumen
problems serious enough to warrant management, with approx-
imately four million ears being syringed annually. Impacted
cerumen causes unpleasant symptoms and is occasionally asso-
ciated with serious sequale, such as hearing loss, social with-
drawal, poor work function and perforated eardrums. The
physiology, clinical signiﬁcance and management implications
associated with excessive and impacted cerumen remain poorly
characterised. The evidence supporting the traditional view that
cerumen plays a biologically or clinically signiﬁcant role in host
defence is weak; rather the consensus seems to be that if any-
thing, cerumen offers a rich medium supporting microbiological
growth. CONCLUSIONS: Patients with impacted cerumen
clearly require effective treatment. However, given a dearth of
rigorous evidence in the literature any attempt at a systematic
assessment of optimal management strategies is exceedingly dif-
ﬁcult. The evidence surrounding the pharmacological manage-
ment of impacted cerumen is inconsistent and few conclusions
can be drawn. There is clearly a need for a deﬁnitive assessment
of the most effective pharmacological strategy for cerumen
removal. Lastly, the causes and management of impacted
cerumen require further investigation.
EYE/EAR/SKIN DISEASES/DISORDERS
EYE/EAR/SKIN DISEASES/DISORDERS—Methods and
Concepts
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AND PRESENCE OF AGE-RELATED MACULAR
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OBJECTIVES: Investigate whether methods employed to reduce
omitted variable bias can be used in a cross-sectional database
to identify a relationship between supplemental vitamin usage
and the presence of Age-related Macular Degeneration (AMD)
in a Latino population. METHODS: Data were obtained from
the Los Angeles Latino Eye Study (LALES) and included 6104
subjects. Data were originally collected to assess the prevalence
of ocular disease and diabetes. Stepwise logistic regressions and
simple logistic regressions for AMD were performed. Propensity
scores were then used to control for selection bias. In the ﬁrst
stage, the probability of receiving vitamin supplements for 10
years or more was modeled using logistic regression. Subjects
were separated into quintiles deﬁned by their propensity scores
and we compared the vitamin supplement/no vitamin supple-
ment groups using a 2-way analysis of variance model. Finally,
the effect of vitamin use on AMD after selection bias adjustment
was estimated using logistic regression. RESULTS: In total, 572
cases of AMD were identiﬁed. When using stepwise logistic
regression, older subjects (OR: 1.043, CI: 1.034–1.052), males
(1.624, 1.157–2.280), and people with income level less than
$20,000 (1.428, 1.006–2.028) were more likely to develop
AMD. Only age and gender were signiﬁcant using logistic regres-
sion and adjusting for potential confounders. The seven covari-
ates found signiﬁcantly different between the vitamin/no vitamin
groups were all non signiﬁcantly different after adjustment for
propensity score quintiles. However, even after selection bias
adjustment, vitamin usage continues to be non-signiﬁcant
(0.896, 0.594–1.352). CONCLUSIONS: Although, propensity
scores helped reduce potential sources of bias in this cross-sec-
tional database, they did not improve the ability to detect a rela-
tionship between vitamin usage and AMD. Other sources of bias,
such as the inability to determine the time of development of
AMD, unknown dosages and speciﬁc vitamins used, could not
be addressed by the use of propensity scores.
GASTROINTESTINAL DISEASES DISORDERS
GASTROINTESTINAL DISEASES DISORDERS—Cost
Studies
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ECONOMIC EVALUATION OF ON-DEMAND MAINTENANCE
THERAPY WITH PROTON PUMP INHIBITORS IN PATIENTS
WITH SYMPTOMATIC GASTROESOPHAGEAL REFLUX
DISEASE—A MONTE-CARLO ANALYSIS FOR ITALY
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OBJECTIVES: On-demand proton pump inhibitor (PPI) main-
tenance therapy is recommended for patients with symptomatic
gastroesophageal reﬂux disease (GERD) in Italy who achieve
symptom remission after 4 weeks of continuous treatment. The
objectives of this analysis are to evaluate the costs to the health
care system (NHS) and to society and effectiveness (quality
adjusted life years) of on-demand maintenance therapy in
patients with symptomatic GERD. METHODS: Decision analy-
sis and Markov modelling of costs and effectiveness up to 12
months. Efﬁcacy data were extracted from seven placebo-
controlled trials; the primary outcome measure was time to treat-
ment discontinuation owing to relapse of symptoms, requiring
continuous therapy. Health state utilities were derived from a
previously published study and data on health care resource util-
isation were obtained from a prospective Italian study that 
followed 577 patients with functional dyspepsia for one year.
RESULTS: Differences in utility scores associated with each PPI,
ranging from 0.731 to 0.745 quality-adjusted life years, were not
statistically different. Annual expected cost, however, were sta-
tistically different among the different drugs and the following
cost-minimization raking was obtained for costs to the NHS and
to society, respectively: rabeprazole (181€, 295€), pantoprazole
(223€, 341€), lansoprazole (249€, 370€), omeprazole 10mg
(297€, 412€), esomeprazole (295€, 419€), omeprazole 20mg
(405€, 528€). Unit cost of PPI was the major determinant of cost
to the NHS, while productivity days lost due to symptoms was
the major determinant of cost to society. CONCLUSIONS:
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On-demand use of rabeprazole for the management of sympto-
matic GERD incurs the least cost in comparison to the other 
PPIs evaluated. Utility gains were comparable for all on-demand
PPIs.
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OBJECTIVES: To asses the cost-effectiveness of two initial man-
agement strategies for the general practitioner in dyspepsia. The
two strategies investigated are prompt endoscopy and a Heli-
cobacter pylori test-and-treat strategy. METHODS: Pharma-
coeconomic data was gathered alongside the SENSE (Strategy:
Endoscopy versus Serology)-study from 1998 up to 2001.
Patients were randomized in the endoscopy (n = 105) and test-
and-treat (n = 118) group. The costs were standardized costs for
1999. Quality of life was measured at inclusion and one year
later, using the validated Dutch translation of the RAND-36
questionnaire. The results obtained were transformed into one
overall score, in terms of Quality Adjusted Life Years (QALYs).
An incremental cost-effectiveness ratio (ICER) was calculated as
incremental cost of test-and-treat over early endoscopy per
QALY gained. For estimating the uncertainty we calculated 95%
uncertainty limits using parametric bootstrap with angular trans-
formation. RESULTS: For the test-and-treat group the total costs
per patient were 511.02€ and the number of QALYs gained was
0.074 per patient. For the endoscopy group this was 748.08€
and 0.064 QALYs gained. The point estimate of the ICER indi-
cated cost-savings and QALYs gained. Parametric bootstrap
uncertainty limits indicate cost-savings per QALY gained
(75.7%) and cost savings per QALY lost ranging from 11,970€
to inﬁnity. CONCLUSIONS: According to our data, the Heli-
cobacter test-and-treat strategy is more cost-effective than
prompt endoscopy in the initial management of dyspepsia in
general practice.
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OBJECTIVES: To compare the cost-effectiveness of esomepra-
zole versus pantoprazole and generic omeprazole from the per-
spective of the statutory health insurance using a decision model
reﬂecting naturalistic treatment behaviour in GERD patients in
Germany. METHODS: The model applies to patients with endo-
scopically veriﬁed GERD receiving PPI therapy and covers a
period of 8 weeks. Therapies included were esomeprazole 20 and
40mg, omeprazole 20 and 40mg and pantoprazole 40mg. Real-
life treatment patterns and resource utilization for acute and
maintenance treatment were derived from 30 physician inter-
views, whereas healing rates after 4 and 8 weeks of treatment
were derived from published literature. Resource utilization
included visits, examinations and laboratory tests at primary
care physicians and specialists, drug treatment of GERD, hospi-
talizations and working incapacity. RESULTS: Total costs per
patient ranged between 137€ for esomeprazole and 202€ for
pantoprazole with total healing rates after eight weeks between
85% (omeprazole) and 96% (esomeprazole). No hospitaliza-
tions were observed and the few sick leaves reported were shorter
than 42 days, inducing no costs from the insurance perspective.
Costs per patient healed varied between 145€ (esomeprazole)
and 218€ (pantoprazole), with most of the treatments ranging
closely around 200€. Due to the relatively small sample size, we
tested the robustness of the results by conducting sensitivity
analyses representing different degrees of standardization in
input parameters. Cost-effectiveness did not differ much in either
scenario; standardizing e.g. physician costs and treatment dura-
tion resulted in costs per patient healed between 163€ (esomepra-
zole) and 210€ (omeprazole). CONCLUSIONS: The results
indicate that esomeprazole is a cost-effective treatment option
for patients with endoscopically veriﬁed GERD treated over 8
weeks. Strongest competitor for esomeprazole is treatment with
generic omeprazole. The current model will be extended to a 6
month period as soon as the data from a currently completed
study will become available.
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GASTROINTESTINAL BLEEDING: COST–EFFECTIVENESS
EVALUATION FROM A EUROPEAN PERSPECTIVE
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OBJECTIVES: To analyze the cost-effectiveness of capsule
endoscopy (CE) in diagnosing obscure gastrointestinal bleeding
(OGIB) from a health care payer perspective in France, the UK,
and Switzerland. METHODS: Based on clinical trial data, a
microsimulation model incorporating ﬁrst- and second-order
Monte Carlo simulation was developed. The model calculates
the costs per correctly diagnosed case in patients with OGIB.
Sensitivity and speciﬁcity for CE and the comparator push
enteroscopy (PE) as well as kind and number of other procedures
performed prior to diagnosis were evaluated from 7 controlled
clinical trials (n = 184). Procedure cost, cost of diagnostic failure
(false positive/negative diagnosis) were considered and incre-
mental cost-effectiveness ratios dependent on disease prevalence
are given. Cost data were estimated from a healthcare payer per-
spective using the “Assurance Maladie” (France), NHS Refer-
ence Cost (UK), and the TARMED (Switzerland). RESULTS:
Sensitivity for CE was 89–99% and 27–60% for PE. Speciﬁcity
values were 90–99% for CE and 50–70% for PE. In all 5 coun-
tries, CE was cost saving when the prevalence of the disease was
10% or higher. Most common use for CE is at a prevalence of
50%. Cost savings at a prevalence of 50% are 1508€ (France),
1695€ (UK) and 2240€ (Switzerland). Probabilistic sensitivity
analyses approved a high robustness for these results. CON-
CLUSIONS: CE proved to have a higher effectiveness than PE
when diagnosing obscure bleeding. Though procedure costs vary
substantially from country to country, incremental analysis
shows that the use of CE has a cost-saving potential in all three
countries.
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OBJECTIVES: Assessing the potential increase in GERD medical
treatment expenses and the impact of on-demand treatment with
